Shanghai Bao Pharmaceuticals Co Ltd is a CN-based company operating in industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2025-12-10. Shanghai Bao Pharmaceuticals Co Ltd is a China-based company principally engaged in research and development of pharmaceutical products. The firm leverages synthetic biology technology to develop and deliver recombinant biologic drugs, targeting conditions with limited treatment options and complex manufacturing challenges. The firm focuses on four areas, including large-volume subcutaneous drug delivery, antibody-mediated autoimmune conditions, drugs in assisted reproduction and recombinant biologic products as transformative alternative to traditional biochemical production. The Company’s Core Products comprise SJ02 (Slonva), a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP), KJ017, a recombinant human hyaluronidase, and KJ103, an innovative recombinant immunoglobulin G (IgG)-degrading enzyme.
02659.HK stock price ended at $101.6 on 星期四, after rising 6.95%
On the latest trading day Jan 15, 2026, the stock price of 02659.HK rose by 6.95%, climbing from $95.05 to $101.60. During the session, the stock saw a volatility of 12.87%, with prices oscillating between a daily low of $91.70 and a high of $103.50. Notably, trading volume dropped by 10.3K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 258.4K shares were traded, equating to a market value of approximately $15.6B.